Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 3/20 | 0.65 |
| ▸ | CES2 | O00748 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6790664 | 0.93 | CES1 (0.65) | CES1CES2LMNAMEN1KMT2A | |
| Bicarbonate SCHEMBL28889042 | 0.92 | CES1 (0.62) | CES1CES2LMNAMEN1KMT2A | |
| SCHEMBL30692971 | 0.91 | MEN1 (0.58) | CES1CES2LMNAMEN1KMT2A | |
| Acetic Acid SCHEMBL11298094 | 0.89 | CES1 (0.59) | CES1CES2LMNAMEN1KMT2A | |
| SCHEMBL7588544 | 0.85 | TDP1 (0.63) | CES1CES2LMNAMEN1KMT2A | |
| SCHEMBL10361101 | 0.85 | CES1 (0.61) | CES1CES2LMNAMEN1KMT2A | |
| SCHEMBL28551178 | 0.82 | CES1 (0.57) | CES1CES2LMNAMEN1KMT2A | |
| SCHEMBL4481419 | 0.82 | CES1 (0.57) | CES1CES2LMNAMEN1KMT2A | |
| SCHEMBL11752809 | 0.82 | CES1 (0.57) | CES1CES2LMNAMEN1KMT2A | |
| SCHEMBL10170602 | 0.80 | MEN1 (0.62) | CES1CES2LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105884833-B | Preparation method and antitumor activity of novel ruthenium complex containing 4, 4 '-dibromo-2, 2' -bipyridyl | 江南大学 | 2020-05-08 | — | — | CN | claimed |
| CN-105884833-B | Preparation method and antitumor activity of novel ruthenium complex containing 4, 4 '-dibromo-2, 2' -bipyridyl | 江南大学 | 2020-05-08 | — | — | CN | disclosed |
| US-20040138228-A1 | Novel compounds with analgesic effect | ASTRAZENECA CANADA INC. | 2004-07-15 | — | — | US | disclosed |
| EP-1408037-A1 | Novel diarylmethylpiperazine and diarylmethylphenyl compounds with analgesic effect | AstraZeneca AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| US-6680321-B1 | 4-((1-PIPERAZINYLMETHYL)-BENZAMIDE DERIVATIVES; HYPOTENSIVE AGENTS; IMMUNOMODULATORS | ASTRAZENECA CANADA, INC. (CA) | 2004-01-20 | — | — | US | disclosed |
| US-6130222-A | Compounds with analgesic effect | ASTRA PHARMA INC. (CA) | 2000-10-10 | — | — | US | disclosed |
| EP-0915855-A1 | NOVEL COMPOUNDS WITH ANALGESIC EFFECT | Astra Pharma Inc. (CA) | 1999-05-19 | — | — | EP | disclosed |
| WO-1997023466-A1 | NOVEL COMPOUNDS WITH ANALGESIC EFFECT | ASTRA PHARMA INC. (CA) | 1997-07-03 | — | — | WO | disclosed |
| WO-1992013897-A1 | AN ANTI-CRUST DECOLORIZED MATERIAL FOR THE POLYMERIZATION OF THE CHLORINATED OLEFINIC MONOMERS | C.I.R.S. COMPAGNIA ITALIANA RICERCA E SVILUPPO S.R.L. (IT) | 1992-08-20 | — | — | WO | disclosed |
| EP-0498142-A1 | An anti-crust decolorized material for the polymerization of the chlorinated olefinic monomers | C.I.R.S. COMPAGNIA ITALIANA RICERCA E SVILUPPO S.R.L. (IT) | 1992-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138228-A1 | Novel compounds with analgesic effect | OPRL1, OPRK1, OPRM1 | CES1 1582/4885CES2 2005/4885LMNA 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.